Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 1, 2022Nature MedicineOpen Access

Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial

View Full Paper
Ask AI
Bookmark
Share

Authors

VSVivek SubbiahPCPhilippe A. CassierSSSalvatore Siena

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Subbiah et al. (2022) studied this question.

synapsesocial.com/papers/6a710b1775498292b70a8596https://doi.org/10.1038/s41591-022-01931-y
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer2010 · 4,493 citations
  2. 2RET rearrangements are actionable alterations in breast cancer2018 · 128 citations
  3. 3Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up2019 · 1,230 citations